Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ret finger protein-like 2 (RFPL2, also known as RING finger protein 79 or RNF79) is a zinc finger protein with a predicted RING-like motif and B30-2 domain, mapped to human chromosome 22q12.2-q13.3[2][3][4]. It is a protein-coding gene and is part of the RFPL gene cluster (including RFPL1 and RFPL3). RFPL2 is predicted to function as a ubiquitin protein ligase and is involved in the regulation of gene expression, innate immune response, and is active primarily in the cytoplasm[3][8]. RFPL2 is highly expressed in the fetal neocortex and is believed to play a role in neocortex organization during development, as well as in other tissues such as the prostate[2]. Diseases associated with RFPL2 include certain forms of epilepsy and muscular dystrophy; however, direct therapeutic targeting or clinical drugs interacting with RFPL2 are not currently established[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ret finger protein-like 2 (RFPL2).